All In Biotech

Drug Trial Radar · NCT02724228

A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)

A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Actual

Start

Jan 26, 2016

Primary completion

Dec 2027

Study completion Feb 2028

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Mar 31, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.

Conditions

  • Achondroplasia

Interventions

  • BMN 111Drug

    BMN 111 will be administered subcutaneously daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Until near final adult height is reached, and up to at least 16 years of age for females and 18 years of age for males, whichever occurs later

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Children's Hospital & Research Center Oakland

    Oakland, California

  • Harbor - UCLA Medical Center

    Torrance, California

  • Ann and Robert H. Lurie Childrens Hospital of Chicago

    Chicago, Illinois

  • Johns Hopkins McKusick - Institute of Genetic Medicine

    Baltimore, Maryland

  • Vanderbilt University

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • Institut Necker

    Paris, France

  • Guys & St. Thomas NHS Foundation Trust Evelina Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.